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The inflammatory response of mammalian cells
to TNF-a can be switched to apoptosis either by
cotreatment with a protein synthesis inhibitor, cyclo-
heximide, or Smac mimetic, a small molecule mimic
of Smac/Diablo protein. Cycloheximide promotes
caspase-8 activation by eliminating endogenous cas-
pase-8 inhibitor, c-FLIP, while Smac mimetic does so
by triggering autodegradation of cIAP1 and cIAP2
(cIAP1/2), leading to the release of receptor interact-
ing protein kinase (RIPK1) from the activated TNF re-
ceptor complex to form a caspase-8-activating com-
plex consisting of RIPK1, FADD, and caspase-8. This
process also requires the action of CYLD, a RIPK1
K63deubiquitinatingenzyme.RIPK1 is critical for cas-
pase-8 activation-induced by Smac mimetic but dis-
pensable for that triggered by cycloheximide. More-
over, Smac mimetic-induced caspase-8 activation
is not blocked by endogenous c-FLIP. These findings
revealed that TNF-a is able to induce apoptosis via
two distinct caspase-8 activation pathways that are
differentially regulated by cIAP1/2 and c-FLIP.
INTRODUCTION
Tumor necrosis factor, TNF-a, is a pleiotropic cytokine inducing
a variety of cellular responses, ranging from inflammatory cyto-
kine production, cell survival, cell proliferation, and paradoxi-
cally, cell death (Varfolomeev and Ashkenazi, 2004). Improper
TNF-a signaling has been implicated in the pathogenesis ofmany
human diseases including cancer, sepsis, diabetes, and autoim-
mune diseases. Therapeutic strategies using soluble receptors
and neutralizing antibodies to inhibit TNF signaling have become
frontline therapies for these autoimmune diseases (Feldmann
and Maini, 2003).
The pleiotropic nature of TNF-a response results from the se-
quential formation of different signaling complexes upon binding
of TNF-a to its receptor, TNF-RI (Micheau and Tschopp, 2003).
Following activation of TNFRI, the death domain at the cytoplas-
mic tail of TNFRI rapidly recruits an adaptor protein, TNF receptor
associated-protein with death domain (TRADD), which subse-
quently recruits other signaling proteins including TNF receptor
associated protein 2 (TRAF2), receptor associated protein kinase1 (RIPK1), and cellular inhibitor of apoptosis proteins cIAP1 and
cIAP2, to form a signaling complex referred as complex I (Chen
and Goeddel, 2002; Karin, 2006; Muppidi et al., 2004). Complex
I then recruits IkB kinase (IKK) complex through the K63-specific
polyubiquitin chain on RIPK1, leading to the activation of NF-kB
(Ea et al., 2006; Li et al., 2006; Wu et al., 2006). NF-kB drives the
transcription of many additional cytokines aswell as several anti-
apoptotic proteins, including cIAP1, cIAP2, and c-FLIP, which
prevent cell death and sustain inflammation (Chu et al., 1997;
Kreuz et al., 2001; Micheau et al., 2001; Wang et al., 1998).
In a process that is still not well characterized, complex I
internalizes and converts into a caspase-8 activating, death
inducing complex, complex II, with additional recruitment of
FADD and procaspase-8 (Micheau and Tschopp, 2003). The ac-
tivity of complex II is normally inhibited by c-FLIP, a protease-
dead caspase-8 homolog that competes for caspase-8 binding
to FADD (Irmler et al., 1997). Such inhibition is relieved either
through activation of a c-FLIP degrading ubiquitin E3 ligase,
Itch, and/or termination of the NF-kB transcriptional activity
by the addition of protein synthesis inhibitors that shut down
c-FLIP synthesis (Chang et al., 2006; Kreuz et al., 2001;
Micheau et al., 2001).
Interestingly, switching TNF signaling to apoptosis was also
observed when cells were cotreated with Smac mimetic, a cell
permeable synthetic compound designed to mimicking the ac-
tivity of Smac/Diablo, a mitochondrial protein that binds inhibitor
of apoptosis proteins including XIAP, cIAP1 and cIAP2 (Du et al.,
2000; Verhagen et al., 2000). Smac binds to the signature BIR
domains of IAP proteins via its N–terminal four amino acid
resides AVPI (Liu et al., 2000; Wu et al., 2000). A mimetic with
a C-2 symmetric dimer of AVPI has been shown to function as
potently and specifically as the native protein and sensitizes a va-
riety of human cancer cells to TNF-a and Trail-induced apoptosis
(Li et al., 2004; Petersen et al., 2007).
Smac (or its mimetics) binds to the BIR3 and BIR2 domains of
XIAP to directly relieve their inhibition of caspase-9 and caspase-
3, 7, respectively (Chai et al., 2000; Li et al., 2004). It also func-
tions as an allosteric activator of the E3 ubiquitin ligase activity of
cIAP1 and cIAP2 after binding to the BIR domains of these pro-
teins, leading to the autodegradation of these two proteins (Du
et al., 2000; Varfolomeev et al., 2007; Vince et al., 2007; Yang
and Du, 2004). The degradation of cIAPs has been shown to fa-
cilitate the activation of both canonical and noncanonical NF-kB
pathways (Varfolomeev et al., 2007; Vince et al., 2007).
It remains puzzling that Smac mimetics stimulate TNFa-in-
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promoting NF-kB activation, which is in general pro-survival. In
the current report, we address this paradox by characterizing
the caspase-8 activation pathway triggered by TNF-a plus
Smac mimetic. These data reveal that TNF-a induces apoptosis
through two distinct caspase-8 activation pathways that are dif-
ferentially regulated by different anti-apoptotic proteins.
RESULTS
Smac Mimetic Induces TNF-a-Dependent Cell Death
without Affecting NF-kB Activation
Wehavepreviously reported thatSmacmimeticpromotesTNF-a-
dependent apoptosis in HeLa cells (Li et al., 2004). In order to de-
termine the prevalence of this response, we screened a panel of
human tumor cell lines from a variety of origins for synergy be-
tween TNF-a and a Smac mimetic. In proximately 40% of tumor
cell lines examined, EC-50 of TNF-a was significantly improved
by coadministration of Smac mimetic (data not shown). Several
tumor lines, including Panc-1 pancreatic carcinoma cells, T98G
glioblastoma cells, H2009 lung carcinoma, MIA-CAPA2 pancre-
atic carcinomacells, andU-2OSosteosarcomacellswere chosen
for further analysis. In these cell lines, TNF-a or Smac mimetic
treatment alone had little effect on cell survival while cotreatment
of the two agents killed cells in a TNF-a dose-dependent manner
(Figure 1A and Figure S1 available online). The cell death was
blocked by z-VAD, a pan caspase inhibitor, indicating the involve-
ment of caspases (Figure S2A). Indeed, TNF-a plus Smac mi-
metic, but not TNF-a alone, increased caspase activity in the
treatedcellswithin2hr (Figure1B).Caspaseactivationwas further
confirmedby theappearanceof activecaspase-8andcaspase-3,
as well as cleaved PARP, a substrate of caspase-3 (Figure S2B).
Smac mimetic treatment of these cells did not affect TNF-a-
induced NF-kB activation since IkB level was rapidly and tran-
siently decreased upon TNF-a stimulation regardless of the
presence of Smac mimetic (Figure 1C). Consistent with this
result, Smac mimetic had no effect on TNF-a-induced NF-kB
luciferase reporter activity (Figure 1D). Similar results were
observed in HEK293T cells (Figure S3).
Smac Mimetic-Induced TNF-a-Dependent Death
Pathway Is Different from the One That Requires
Cycloheximide
The inability of Smacmimetic to tune down TNF-a-induced NF-kB
activation while still activating caspase-8 is quite puzzling. In most
cases, NF-kB-induced gene expression needs to be downregu-
lated in order for caspase-8 to be activated. Since c-FLIP has
been proposed to mediate the inhibitory effect of NF-kB on cas-
pase-8 activation (Kreuz et al., 2001; Micheau et al., 2001), we ex-
amined the effect of Smac mimetic on c-FLIP. As shown in Fig-
ure 2A, the level of c-FLIP did not change upon Smac mimetic
treatment. Cotreatment of Smac mimetic with TNF-a resulted in
the appearance of a 43/44 KD species of c-FLIP. Knockdown of
Figure 1. Smac Mimetic Induces TNF-a-
Dependent Cell Death without Affecting
NF-kB Activation
(A) Panc-1 cells were treated with indicated in-
creasing concentration of TNF-a in the presence
or absence of 100 nM Smac mimetic for 48 hr.
Cell survival was determined by measuring ATP
levels using Cell Titer-Glo kit. Data were repre-
sented as mean ± standard deviation of dupli-
cates.
(B) Panc-1 cells were treated with 100 ng/ml TNF-
a in the presence or absence of 100 nM Smac mi-
metic. Identical concentrations were used in later
experiments unless otherwise stated. Cell lysates
were prepared using freezing and thawing method
as described in Experimental Procedures. Cas-
pase activity was determined using a caspase-3
flurogenic substrate. Data were represented as
mean + standard deviation of three independent
experiments.
(C) Panc-1 cells were treated as indicated and
later were harvested in lysis buffer as described
in Experimental Procedures. Changes in IkB levels
were measured by western blot analysis. b-actin
was used as loading control. T: TNF-a; S: Smac
mimetic.
(D) NF-kB activation luciferase reporter assay in
T98G cells. T98G cells were transfected and
treated as described in experimental procedures.
Fold activation was calculated by normalizing fire-
fly luciferase activity/renilla luciferase activity of
each treatment to that of z-VAD treatment. Data
were represented as mean + standard deviation
of duplicates. All experiments were repeated at
least three times with similar results.694 Cell 133, 693–703, May 16, 2008 ª2008 Elsevier Inc.
Figure 2. c-FLIP Differentially Regulates Smac Mimetic or Cycloheximide-Induced TNF-a-Dependent Apoptosis
(A) After Smac mimetic and/or TNF-a treatment, Panc-1 cells were harvested and an aliquot of cell lysate was subjected to western blot analysis of c-FLIP and b-
actin levels.
(B) To determine the effect of cycloheximide on c-FLIP, Panc-1 cells were treated with cycloheximide or PBS vehicle for 1 hr prior to the treatment of TNF-a. The
time point of TNF-a addition was designated as 0 hr. Four microgram per ml of cycloheximide was used to treat the cells. Identical concentration was used in later
experiments unless otherwise stated. At the indicated time points, cell lysates were collected and subjected to western blot analysis of c-FLIP and b-actin levels.
(C) Parental or Flag-c-FLIP stably overexpressing Panc-1 cells (Clone 2–9 and Clone 2–8) were treated for 48 hr and cell viability was determined by measuring
ATP levels. Cell survival rate was normalized to that of the corresponding treatment without TNF-a. Data were represented as mean ± standard deviation of du-
plicates.
(D) Cell lysates from parental Panc-1 cells and Flag-c-FLIP overexpressing stable cells were collected and subjected to western blot analysis of c-FLIP and b-
actin levels. To be noted, the c-FLIP encoded by the transgene migrated slightly bigger on the SDS-PAGE because of a FLAG tag at its N-terminus. All exper-
iments were repeated at least three times with similar results.caspase-8 by RNAi blocked this cleavage event, indicating that c-
FLIP cleavage requires caspase-8 (Figure S4). In contrast to Smac
mimetic, cycloheximide, a protein synthesis inhibitor, decreased
basal as well as elevated level of c-FLIP induced by TNF-a (Fig-
ure 2B). Coadministration of TNF-a with cycloheximide induced
caspase activation and subsequent apoptosis (Figures S5A and
S5B). Silencing of c-FLIP using RNAi was sufficient to mimicking
cycloheximide treatment (Figures S5C–S5E). Consistent with the
effects of cycloheximide and Smac mimetic on c-FLIP level, over-
expression of c-FLIP completely blocked TNF-a plus cyclohexi-
mide-induced cell death, but had much less effect on TNF-a plus
Smacmimetic-induced cell death (Figure 2C). These data suggest
that Smac mimetic-induced TNF-a-dependent apoptosis is differ-
ent from that induced by cycloheximide or c-FLIP RNAi.
RIPK1 Is Essential for Smac Mimetic-Stimulated, but
Not for Cycloheximide-Sensitized TNF-a-Induced
Apoptosis, while FADD Is Required for Both Pathways
Consistent with our previous report (Petersen et al., 2007),
knockdown of RIPK1 by RNAi in all tumor cells examined
blocked TNF-a plus Smac mimetic-induced apoptosis (Fig-
ures 3A and S6). Identical knockdown of RIPK1 had no effecton apoptosis induced by TNF-a plus cycloheximide (Figure 3A).
In contrast, knockdown of caspase-8 rescued cell death in both
cases. Consistent with what was observed with cycloheximide,
cell death induced by TNF-a plus c-FLIP RNAi was not affected
by knockdown of RIPK1, but was rescued by knockdown of
caspase-8 (Black bars in Figure 3B). In TNF-a plus c-FLIP
RNAi treated cells, most of the surviving cells were further killed
by the addition of Smac mimetic (Grey bars in Figure 3B). Inter-
estingly, only this portion of cell death was rescued by RIPK1
RNAi, suggesting that both RIPK1-dependent and RIPK1-inde-
pendent cell death pathways can be simultaneously turned on
by TNF-a. To further validate the role of RIPK1 in apoptosis,
tetracycline-inducible RIPK1-shRNAstable cell lineswere gener-
ated and their responses to TNF-a plus Smac mimetic or cyclo-
heximide were tested. As shown in Figure 3F, RIPK1 expression
in these cells was efficiently knocked down by the addition of tet-
racycline to the cell culture media. Consistent with what was
observed using transient siRNA transfection, TNF-a plus Smac
mimetic-induced apoptosis in these cells was fully blocked in
the presence of tetracycline (Figure 3D) while the TNF-a plus cy-
cloheximide-induced apoptosis was barely affected (Figure 3E).
Unlike in RIPK1 null cells (Kelliher et al., 1998), TNF-a treatmentCell 133, 693–703, May 16, 2008 ª2008 Elsevier Inc. 695
Figure 3. RIPK1 Is Essential for Smac Mimetic, but Not for Cycloheximide-Induced TNF-a -Dependent Cell Death
(A and B) Panc-1 cells were transfected with the indicated siRNAs to determine RIPK1 dependence. Forty-eight hours post-transfection, cells were treated as
indicated. After another 24 hr, cell viability was determined by measuring ATP levels. Data were represented as mean + standard deviation of duplicates. Similar
results were observed using individual oligoes from siRNA pools (data not shown).
(C) The RNAi efficiency of RIPK1 siRNA. Forty-eight hours post transfection, cell lysates from cells transfectedwith luciferase (Luc) or RIPK1 siRNAwere collected
andsubjected towesternblot analysis ofRIPK1andb-actin levels.Westernblot analysis of caspase-8andc-FLIPRNAi efficiency is shown inFiguresS4BandS5D.
(D–H) H2009RIPK1-shRNA, RIPK1wild-type (WT) with shRNA target Scramble (Scr), or RIPK1 kinase deadmutant (K45A) Scr stable cells generated as described
in the Experimental Procedureswere treatedwith or without 0.03 mg/ml tetracycline for 72 hr prior to any additional treatment. (D) RIPK1-shRNA cells were treated
with or without TNF-a plus Smac mimetic for additional 72 hr. Cell viability was determined by measuring ATP levels. Data were represented as mean + standard
deviation of duplicates. (E) RIPK1-shRNA cells were treatedwith cycloheximide (10 mg/ml) or PBS vehicle for 1 hr prior to the treatment of TNF-a or PBS vehicle for
additional 24 hr. Cell viabilitywasdeterminedbymeasuring ATP levels. Datawere represented asmean+ standard deviation of duplicates. (F) After 72 hr treatment
with orwithout tetracycline, cell lysateswere collected and subjected towestern blot analysis ofRIPK1and b-actin levels. (G)H2009RIPK1-WTScr or RIPK1-K45A
Scr stable cells were treated with or without TNF-a plus Smacmimetic for additional 48 hr. Cell viability was determined bymeasuring ATP levels. Data were rep-
resented asmean+ standard deviation of duplicates. (H) After 72 hr treatmentwith orwithout tetracycline, cell lysateswere collected and subjected towestern blot
analysis of RIPK1 and b-actin levels. To be noted, the RIPK1 encoded by the transgene migrated slightly bigger on the SDS-PAGE because of a FLAG tag at its C
terminus. All experiments were repeated at least three times with similar results.alone had no effect on cell death (Figure S7A). It is interesting
to note that although RIPK1 was knocked down to a level that
TNF-a plus Smac mimetic-induced apoptosis could not occur,
the TNF-a-induced NF-kB activation proceeded normally
(Figure S7B). These observations indicated that different levels
of RIPK1 are required for NF-kB and caspase-8 activation. The
observed apoptosis defect was rescued by the expression of
a wild-type RIPK1 transgene with the shRNA targeting sequence
silently mutated such that it is resistant to shRNA knockdown
(Figure 3G, left panel). The transgene is under control of the696 Cell 133, 693–703, May 16, 2008 ª2008 Elsevier Inc.same tetracycline-inducible promoter so that upon the addition
of tetracycline, the transgene was simultaneously induced while
endogenousRIPK1was being knockeddown (Figure 3H). In con-
trast towild-typeRIPK1, expressingakinasedeadmutant formof
RIPK1 transgene failed to rescue apoptosis (Figure 3G, right
panel), indicating that the kinase activity of RIPK1 is essential
for TNF-a plus Smac mimetic-induced apoptosis.
The roles of two other TNF-a signaling molecules, TRADD and
FADD, in TNF-a plus Smac mimetic-induced apoptosis were
also investigated. As shown in Figures 4A and 4B, knockdown
Figure 4. FADD and TRADD Play Opposite Roles in Smac Mimetic-Induced TNF-a-Dependent Apoptosis
(A and B) Panc-1 cells were transfected with the indicated siRNAs for 48 hr prior to any treatment. (A) Cells were treated with TNF-a plus Smac mimetic for the
indicated time. Cell lysates were collected for western blot analysis of PARP, FADD, TRADD, and b-actin levels. * indicates a cross reactive band. (B) Cells were
treated with or without TNF-a plus Smac mimetic for 24 hr. Cell viability was determined by measuring ATP levels. Data were represented as mean + standard
deviation of duplicates. The effect of TRADD RNAi was verified using individual oligoes from siRNA pool (data not shown).
(C) Parental or stably expressing dominant negative FADD Panc-1 cells were treated as indicated for 48 hr and cell viability was determined by measuring ATP
levels. Cell survival rate was normalized to that of the corresponding treatment without TNF-a. Data were represented asmean ± standard deviation of duplicates.
(D) Cell lysates from parental Panc-1 cells and FADD dominant negative cells were collected and subjected to western blot analysis of FADD and b-actin levels. All
experiments were repeated at least twice with similar results.of TRADD by siRNA transfection enhanced caspase activation
and cell death while knockdown of FADD partially blocked
them. The inability of FADD RNAi to fully rescue apoptosis is
probably due to the limited knockdown efficiency. To further
confirm the role of FADD, we generated Panc-1 cells expressing
a dominant negative (DN) version of FADD, containing only the
Death Domain and C-terminal tail. As shown in Figure 4C, both
the Smac mimetic-induced and the cycloheximide-induced
TNF-a-dependent apoptosis were abolished in FADD-DN cells,
suggesting that FADD is involved in both pathways.
TNF-a Plus Smac Mimetic Induces the Formation
of a Large Caspase-8 Activating Complex Consisting
of RIPK1, FADD, and Caspase-8
Consistentwith thepivotal roles of bothRIPK1andFADD inSmac
mimetic-induced apoptosis, RIPK1 and FADD were detected in
a caspase-8 immunocomplex upon TNF-a plus Smac mimetic
stimulation (Figure 5A). Treatments of both TNF-a and Smac mi-
metic are required for the complex formation. Addition of z-VADenhanced the complex formation (data not shown), probably by
preventing the complex from falling apart after caspase-8 activa-
tion. In cells that were stably transfected with a tetracycline-in-
ducible RIPK1-shRNA construct, silencing of RIPK1with tetracy-
cline abolished the interaction between caspase-8 and FADD
(Figure 5B), suggesting that RIPK1 is upstream of FADD/cas-
pase-8 interaction. In agreement with the notion that TRADD
plays a negative role in Smac mimetic-induced apoptosis, more
RIPK1-dependent caspase-8 activation complex was formed
when TRADD expression was silenced by siRNA (Figure S8).
Also consistent with the requirement of RIPK1 kinase activity in
apoptosis, the interaction between caspase-8 and FADD was
largely attenuated in cells expressing the kinase dead mutant of
RIPK1 (Figure 5C). We noticed that only a small fraction of RIPK1
and FADD from the total cellular pool was associated with cas-
pase-8 after the TNF-a plus Smacmimetic treatment (Figure 5D).
Interestingly, FADD in the caspase-8 immunocomplex migrated
slightly slower on SDS-PAGE, indicating that FADD might be
modified in the complex.Cell 133, 693–703, May 16, 2008 ª2008 Elsevier Inc. 697
Figure 5. SmacMimetic Plus TNF-a Induces the Formation of a Large Caspase-8 Activating Protein Complex Consisting of RIPK1 and FADD
Panc-1 (A, D, E, and F) or H2009 stable cells (B and C) were treated as indicated and lysates were immunoprecipitated with a caspase-8 antibody as described in
Experimental Procedures. Twentymicro-molar of Pan-caspase inhibitor z-VAD (Z) was added to prevent full activation of caspase-8 and subsequent dissociation
from the complex. Identical concentration was used in later experiments unless otherwise stated. The caspase-8 immunocomplex was eluted by acid (A, B, and
C) or caspase-8 peptide (D, E, and F). RIPK1, FADD, and caspase-8 levels were measured by western blot analysis. (A) Time course of RIPK1/FADD/caspase-8
complex formation. H2009 RIPK1-shRNA (B) or H2009 RIPK1-WT Scr and H2009 RIPK1-K45A Scr cells (C) were treated with or without 0.03 mg/ml tetracycline
for 72 hr and cells were then treated as indicated for additional 6 hr. D: DMSO. * indicates a cross reactive band of IgG. (D and E) Panc-1 cells were treated for 3 hr.
(D) RIPK1, caspase-8, and FADD protein levels in the cell lysates (Input) were compared with those in the caspase-8 immunocomplex. One percent of input and
the whole caspase-8 peptide elution were used for western blot analysis. (E) One eighth of the caspase-8 peptide elution (1st elution) was saved for Western blot
analysis. The rest of elution was diluted in lysis buffer and further immunoprecipitated using an anti-FADD antibody. The entire acid elution of FADD immunocom-
plex (2nd elution) was used for Western blot analysis. * indicates a cross reactive band of IgG. (F) Fifty microliters of caspase-8 peptide elution was loaded on to
Superose 6 3.2/30 column. One hundred microliters per fraction was collected and half of it was analyzed for RIPK1, caspase-8 and FADD levels. All experiments
were repeated at least three times with similar results.To confirm that RIPK1 and FADD are present in the same cas-
pase-8complex, theantigenicpeptide-elutedcaspase-8complex
was further immuno-precipitated with an anti-FADD antibody. As
shown inFigure5E,RIPK1 that interactedwithcaspase-8wasalso
bound to FADD.Amajority of eluted caspase-8, however, was not
associated with FADD. Consistent with this result, most caspase-
8 migrated as a monomer on a gel filtration column (Figure 5F).
Only in TNF-a, Smac mimetic, and z-VAD cotreated sample,
a small portion of caspase-8 comigrated with RIPK1 and FADD
in the column at a position between the void volume (5million Dal-
tons) and a molecular size marker of 670 KD, indicating the oligo-
meric nature of this complex. We did not detect any TRADD and
TRAF2 in this complex (data not shown).
Smac Mimetic-Induced cIAP Autodegradation Is
Required for the Formation of RIPK1-Dependent
Caspase-8 Activation Complex
It has been previously reported that ectopic expression of the
mature cytosolic form of Smac selectively degrades cIAP pro-
teins in cells (Yang and Du, 2004). Since both cIAP1 and cIAP2
are associated with TNFRI, we investigated whether our Smac
mimetic can induce cIAP degradation, and whether such an
event affects the formation of RIPK1-dependent caspase-8698 Cell 133, 693–703, May 16, 2008 ª2008 Elsevier Inc.complex. As shown in Figure 6A, when treated with Smac mi-
metic, cellular cIAP1 level was rapidly decreased within 5 min
and completely disappeared after 20 min. The level of cIAP2
was also decreased, but to a lesser degree. The Smac mimetic
effect on cIAP1/2 levels was independent of TNF-a signaling
and was specific to cIAPs, not XIAP (Figure 6A and 6B). In con-
trast, cycloheximide did not alter cIAP1/2 levels (Figure 6A), sug-
gesting that cIAP degradation is a specific event in Smac mi-
metic-induced caspase-8 activation.
Smac mimetic-induced cIAP degradation is mediated through
the proteasome pathway since it was blocked by a proteasome
inhibitor, MG-132 (Figure 6B). Moreover, Smac mimetic de-
creased the levels of ectopically expressed wild-type, but not
cIAP ring finger mutants with deficient E3 ubiquitin ligase activity
(Figure S9) (Yang et al., 2000), suggesting that Smac mimetic
stimulates cIAP autodegradation. This induced cIAP degrada-
tion has also been observed with two independently designed
Smac mimetics (Varfolomeev et al., 2007; Vince et al., 2007).
Pretreatment of MG-132 also completely blocked the cas-
pase-8 activating complex formation (Figure 6C), indicating the
importance of cIAP degradation in the Smac mimetic-induced
caspase-8 activation. To confirm the requirement of cIAP elimi-
nation for RIPK1-dependent caspase-8 complex formation, we
knocked down these IAP proteins using siRNA oligoes. As
shown in Figure 6D, double knockdown of cIAP1 and cIAP2 was
sufficient to allow the formation of RIPK1/FADD/caspase-8 com-
plex in response to TNF-a even in the absence of Smac mimetic.
In comparison with recombinant proteins, we estimate that intra-
cellular cIAP1 concentration is about 5-fold higher than cIAP2
(Figure S10). Interestingly, cIAP2 levels were upregulated when
cIAP1 was silenced (Figure 6E), probably due to the fact that
cIAP1 is an endogenous E3 ubiquitin ligase for cIAP2 (Conze
et al., 2005). This data underscores the necessity of knocking
down both cIAP1 and cIAP2 to mimic the Smac mimetic effect
even though cIAP1 accounts for over 80% of cellular cIAPs.
TripleknockdownofXIAP,cIAP1andcIAP2usingsiRNAoligoes
induced caspase activation, as well as cell death, in the presence
ofTNF-a (FigureS11). This reproduces theeffectofSmacmimetic.
Silencing of only one or two IAP genes had much less effect
(FigureS11 anddata not shown). Taken togetherwithour previous
observations (Li et al., 2004), we conclude that Smac mimetic in-
duces TNF-a-dependent caspase activation by two means: first,
by stimulating cIAPs autodegradation to facilitate the formation
of a RIPK1-dependent caspase-8 activation complex; second,
by removing XIAP inhibition of downstream caspases.
Degradation of cIAPs Triggers the Release
of RIPK1 from the Receptor Complex
Upon TNF-a stimulation, both RIPK1 and cIAP1/2 were rapidly
recruited to TNF-a receptor (Figure 7A). In the presence of
Smac mimetic, lesser amount of cIAPs, especially cIAP1, were
detected in the receptor complex, probably due to Smac
mimetic-induced cIAP degradation. On the other hand, RIPK1
was still recruited to the receptor and was poly-ubiquitinated.
In the presence of Smacmimetic, RIPK1 seemed to be deubiqui-
tinated and dissociated from the receptor faster than in controls.
Since RIPK1 and cIAPs coreside within the TNF-a receptor com-
plex upon ligand stimulation, we speculate that cIAPs might trap
RIPK1 in the receptor complex through direct interaction and
Smac mimetic releases RIPK1 from the receptor by degrading
cIAP proteins. Due to the fact that only very low amounts of
RIPK1 and cIAPs were recruited to the receptor and the transient
nature of the receptor complex, we were unable to detect direct
interaction between endogenous RIPK1 and cIAPs. However,
when coexpressed in HEK293T cells, it was evident that RIPK1
can specifically interact with both cIAP1 and cIAP2 proteins
(Figure 7B). Using series of cIAP1 truncation constructs, we
mapped the Bir2 and Bir3 domains within cIAP1 as crucial for
its interaction with RIPK1 (Figures 7C and S12A). Interestingly,
the biotinylated-Smac mimetic binds cIAP1 mainly through its
Bir3 domain (Figures 7C and S12B).
Deubiquitination of RIPK1 Is Required to Activate the
RIPK1-Dependent Caspase-8 Activating Complex
Nearly the entire population of RIPK1 in the receptor complex is
poly-ubiquitinated (Figure 7A), while what is present in the
RIPK1/FADD/caspase-8 complex is not (Figure 5). This observa-
tion suggests that deubiquitination of RIPK1 occurs before
RIPK1 is incorporated into the caspase-8 activating complex.
Figure 6. cIAP Degradation Is Required for
Smac Mimetic-Induced RIPK1/FADD/Cas-
pase-8 Complex Formation
(A) Panc-1 cells were treated as indicated. cIAP1,
cIAP2, XIAP, and b-actin levels were measured by
western blot analysis.
(B and C) Prior to Smac mimetic and/or TNF-
a treatment, cells were treated with 100 mM MG-
132 or DMSO vehicle control for 1 hr. (B) Cells
were treated for additional 1 hr and harvested for
western blot analysis of cIAP1, cIAP2, XIAP, and
b-actin levels. Pan cIAP antibody used here de-
tected both cIAP1 and cIAP2 proteins, but with
much higher affinity for cIAP2. (C) Cells were
treated for additional 3 hr and harvested for cas-
pase-8 immunoprecipitation. The levels of
RIPK1, FADD, and caspase-8 in the immunocom-
plex were determined by western blot analysis.
(D) Panc-1 cells were transfected with luciferase
(Luc), cIAP1, and/or cIAP2 siRNA. Forty-eight
hours post transfection, cells were treated as indi-
cated for 4 hr. Cells were then harvested and ana-
lyzed for the caspase-8 immunocomplex as de-
scribed in Experimental Procedures. Similar
results were observed using another set of siRNA
oligoes against cIAP1 or cIAP2 (data not shown).
(E) The RNAi efficiency of cIAP1/2 siRNAs. Forty-
eight hours post transfection, cell lysates from
cells transfected with respective siRNA(s) were
collected and subjected to western blot analysis
of cIAP1, cIAP2, and b-actin levels. All experi-
ments were repeated at least three times with
similar results.Cell 133, 693–703, May 16, 2008 ª2008 Elsevier Inc. 699
We therefore testedwhether CYLD, a RIPK1 deubiquitinating en-
zyme (DUB), was required for Smacmimetic-induced caspase-8
activation (Wright et al., 2007). Indeed, knocking down CYLD
with a siRNA oligo decreased the TNF-a plus Smac mimetic-in-
duced apoptosis (Figure 7D), as well as caspase-8 activating
complex formation (Figure 7E), confirming that deubiquitination
of RIPK1 by CYLD is a prerequisite step for Smac mimetic-
induced caspase-8 activation.
DISCUSSION
TNF-a Induces Two Caspase-8 Activation Pathways
The above-described results support a model of TNF-a-induced
apoptosis (Figure S13). Upon binding to TNFR-I, TNF-a is able to
induce apoptosis through two distinct caspase-8 activation
pathways that can be characterized by their differential depen-
dence on RIPK1. The pathway that is independent of RIPK1
is primarily inhibited by c-FLIP. This pathway can be turned
on by the inhibition of protein synthesis with cycloheximide
or more specifically, by knockdown of c-FLIP. Since c-FLIP level
Figure 7. SmacMimetic Triggers RIPK1 Re-
lease from the Receptor and Deubiquitina-
tion of RIPK1 Is Required for RIPK1-Depen-
dent Caspase-8 Activation
(A) After the indicated treatment, receptor com-
plex was captured with GST pull-down as de-
scribed in the Experimental Procedures. TNF-RI,
RIPK1, and cIAP1/2 levels in the receptor complex
were measured by western blot analysis.
(B) HEK293T cells were transfected with RIPK1
and/or cIAP expression plasmids. Forty-eight
hours post transfection, cells were harvested for
immunoprecipitation with HA agarose beads as
described in experimental procedures. Flag, HA,
and b-actin antibodies were used for western
blot analysis.
(C) Mapping of RIPK1 or Smac mimetic interaction
sites on cIAP1. Experiments are described in de-
tails in Figure S12.
(D and E) Panc-1 cells were transfectedwith the in-
dicated siRNAs. Forty-eight hours post transfec-
tion, cells were treated for additional 24 hr (D) or
3 hr (E). (D) Cell viability was determined by mea-
suring ATP levels. Data were represented as
mean + standard deviation of duplicates. Similar
result was obtainedwith another set of siRNA oligo
against CYLD (data not shown). (E) Cells were har-
vested and analyzed for caspase-8 immunocom-
plex as described in Experimental Procedures.
(F) RNAi efficiency of CYLD siRNA. Forty-eight
hours post transfection, cell lysates from cells
transfected with respective siRNA were collected
and subjected to western blot analysis of CYLD
and b-actin levels. All experiments were repeated
at least three times with similar results.
is upregulated by NF-kB, this pathway is
shut off when NF-kB is on. In contrast,
the caspase-8 activation pathway trig-
gered by TNF-a plus Smacmimetic abso-
lutely requires RIPK1. Knockdown of RIPK1 in a variety of cell
types blocked this form of apoptosis.
Smac mimetic-induced caspase-8 activation pathway seems
less sensitive to c-FLIP inhibition. Ectopic expression of c-FLIP
blocks TNF-a plus cycloheximide-induced apoptosis much
more efficiently than that induced by Smacmimetic. The inability
of endogenous c-FLIP to block this form of caspase-8 activation
explained the puzzling observation that apoptosis still occurs
despite that Smac mimetics do not downregulate NF-kB. We
reason that there are perhaps more caspase-8 activating com-
plexes formed in the latter case, whichmay overwhelm the inhib-
itory capacity of endogenous c-FLIP. Consistently, there was
much less FADD associated with caspase-8 in cells treated with
TNF-a plus cycloheximide compared to that treated with TNF-
a plus Smac mimetic, even though PARP cleavage, an indicator
of caspase activity, was comparable in both cases (Figure S14).
Another distinction between these two caspase-8 activation
pathways is the negative role of TRADD in TNF-a plus Smac mi-
metic-induced apoptosis. Knockdown of TRADD enhances this
form of apoptosis and promotes more RIPK1/FADD/caspase-8700 Cell 133, 693–703, May 16, 2008 ª2008 Elsevier Inc.
complex formation (Figure 4B and Figure S8). This observation
could be due to competitive binding of RIPK1 and TRADD to
the receptor as has been previously proposed (Jin and El-Deiry,
2006; Zheng et al., 2006).
The Dual Role of RIPK1 in Promoting Survival and Death
Whether RIPK1 is pro-apoptotic or anti-apoptotic has been con-
troversial ever since RIPK1 was identified (Stanger et al., 1995).
Its pro-apoptotic role was first discovered with the observation
that ectopic expression of RIPK1 evoked apoptosis in trans-
fected cells. Soon after, it was shown that in addition to stimulat-
ing apoptosis, ectopic expression of RIPK1 also induced NF-kB
activation (Hsu et al., 1996). Therefore, RIPK1 was proposed to
have dual functionality in promoting both apoptosis and survival
in TNF-a signaling. However, this view was quickly changed with
the generation of RIPK1 null cells. RIPK1 knockout mice were
born normally, but died within three days after birth, due to ex-
tensive apoptosis in both lymphoid and adipose tissues (Kelliher
et al., 1998). RIPK1/ fibroblasts were much more sensitive to
the TNF-a-induced apoptosis than RIPK1+/+ fibroblasts. More-
over, RIPK1/ fibroblasts failed to activate NF-kB in response
to TNF-a. Similar phenomenon was observed in RIPK1 null Ju-
rkat cells (Ting et al., 1996). These results indisputably estab-
lished RIPK1 as an essential player in the TNF-a-induced NF-
kB activation, but leave its role in the TNF-a-induced apoptosis
in doubt.
The results reported here reconcile the disparity between
these previous studies. The current study revealed that RIPK1
is indeed involved in the TNF-a-induced apoptotic pathway,
but divergent from the RIPK1-independent, c-FLIP-sensitive
one used in RIPK1 null cells. Consistently, we noticed that in
RIPK1 null Jurkat cells, c-FLIP level was dramatically decreased
and the cells were killed with TNF-a alone (Figure S15). While in
cells expressing RIPK1, RIPK1 is recruited to TNF-RI upon
TNF-a stimulation, and gets K63-polyubiquinated, leading to
the association of IKK complex and subsequently activation of
NF-kB (Ea et al., 2006; Li et al., 2006; Wu et al., 2006). Later,
due to Smac (mimetics)-induced cIAP degradation, RIPK1 is
deubiquitinated and released from the receptor, therefore tran-
siting from the prosurvival complex into the cell death-inducing
complex capable of recruiting FADD and caspase-8.
Two important aspects of RIPK1 in this life and death decision
making are the ubiquitination status and the kinase activity of
RIPK1. Polyubiquitination status of RIPK1 on the receptor may
well dictate its functional role as pro or anti-apoptotic player, as
previously suggested (O’Donnell et al., 2007). On the other
hand, the kinase activity of RIPK1 is essential for its ability to
promote caspase-8 activating complex formation and subse-
quent apoptosis (Figure 5C and 3G), but dispensable for NF-kB
activation (Hsu et al., 1996). It is interesting to note that the kinase
activity of RIPK1 is also required for TNF-a-induced necrosis
(Holler et al., 2000). Thus, RIPK1 may also serve as a critical
molecular connection between apoptotic and necrotic death.
The Molecular Mechanism of RIPK1-Dependent
Caspase-8 Activation
Although the majority of RIPK1, FADD, and procaspase-8 are
present in the cytosol, they do not interact with each other. Wehypothesize that recruitment to the TNF receptor complex is
a rite of passage for RIPK1 to gain the ability to recruit FADD
and caspase-8. Mechanistically, this may require RIPK1 to
form some kind of oligomer in the receptor complex. Although
the stoichiometry of RIPK1 in the receptor complex has not
been determined, it is conceivable that RIPK1 may oligomerize
through its death domain upon recruitment to the trimerized
receptor. Interestingly, although RIPK1 in the receptor complex
is K63-poly-ubiquitinated (Figure 7A) (Ea et al., 2006; Li et al.,
2006; Wu et al., 2006), RIPK1 in the FADD/caspase-8 complex
is not (Figure 5). The requirement of CYLD in forming RIPK1-
dependent caspase-8 complex indicates that deubiquitination
of RIPK1 by CYLD is an essential step in this process. It also
supports our hypothesis that RIPK1 has to go through the re-
ceptor to gain the ability to activate caspase-8 because the re-
ceptor complex is where it gets polyubiquitinated. Whether
RIPK1 deubiquitination occurs before or after its dissocia-
tion from the receptor, and whether the deubiquitination is
required for its dissociation from the receptor need further
determination.
CYLDhasbeen shown to be a tumor suppressor gene in Famil-
ial Cylindromatosis with affected patients suffer predisposition to
multiple tumors of the skin appendages (Bignell et al., 2000). In
light of its role in promotingRIPK1-dependent caspase-8 activat-
ing complex, cells missing this protein will have sustained high
NF-kB activity, and be defective in promoting apoptosis, both
of which may contribute to the cancer development.
Once activated RIPK1 is released from the receptor, it is
primed to recruit FADD and procaspase-8. This large complex
may provide a platform for caspase-8 activation, similar to those
reported for other initiator caspase activation (Martinon et al.,
2002; Tinel and Tschopp, 2004; Zou et al., 1999). Interestingly,
FADD is modified in this RIPK1-dependent caspase-8 activating
complex (Figure 5D), and the modification is not simply phos-
phorylation (L.Wang and X.Wang, unpublished results). Charac-
terization of FADD modification may further illustrate the
biochemical steps of caspase-8 activation.
Physiological Significance of RIPK1-Dependent
Caspase-8 Activation Pathway
The two TNF-a-dependent caspase-8 activation pathways may
be regulated by different physiological signals. The RIPK1-inde-
pendent pathway is controlled by the level of c-FLIP, which is
tightly managed by the balance between survival and stress sig-
nals. Survival signals, such as NF-kB activation (Kreuz et al.,
2001; Micheau et al., 2001) and PI-3 kinase activation (Panka
et al., 2001), can boost intracellular c-FLIP level. In contrast,
stress signals, such as JNK activation, lead to decreased
c-FLIP level by accelerating its degradation (Chang et al., 2006).
The RIPK1-dependent pathway is controlled by cIAPs. Their
levels are much less sensitive to protein synthesis rate since
cycloheximide has minimal immediate effects on their levels
(Figure 6A). Instead, they are controlled by allosteric activation
of their ring finger domain ubiquitin ligase by the binding of
Smac or Smacmimetic to the BIR3 domain, leading to their auto-
degradation (Figures 6 and 7C) (Varfolomeev et al., 2007; Vince
et al., 2007; Yang andDu, 2004). Since Smac protein normally re-
sides in the mitochondria, the release of Smac fromCell 133, 693–703, May 16, 2008 ª2008 Elsevier Inc. 701
mitochondria is necessary for it to evoke TNF-a-dependent cell
death. Therefore, the activation of this pathway may well depen-
dent on the state of mitochondria in TNF-a stimulated cells. It
was reported that in a cell line expressing nondegradable mutant
IkB, TNF-a induced selective release of Smac, but not cyto-
chrome C, from mitochondria, through sustained JNK activation
(Deng et al., 2003). Knockdown of endogenous Smac blocked
this TNF-a-induced cell death. Thus, sustained JNK activation,
in addition to increasing c-FLIP degradation, might also stimu-
late caspase-8 activation via endogenous Smac. Moreover,
other apoptotic stimuli that target mitochondria could potentiate
the TNF-a-induced apoptosis by inducing the release of endog-
enous Smac.
Since substantial percentage of tumor cells shows autocrine
TNF-a activity, characterizing the contribution of these two
different caspase-8 activation pathways could be critical impor-
tance in guiding the Smac mimetic-based therapy in clinics.
EXPERIMENTAL PROCEDURES
Please also see Supplemental Data.
Cell Survival Assay
Cell survival analysis was performed using the Cell Titer-Glo Luminescent Cell
Viability Assay kit (Promega) following manufactory instruction with minor
modification. In brief, 25 ml of Cell Titer-glo reagent was added to the cell
culture medium. Cells were place on a shaker for 10 min and were then incu-
bated at room temperature for an additional 10 min. Luminescent reading was
carried on Tecan SPECTRAFluor Plus reader (Tecan).
Plasmid and siRNA Transfection
In general, plasmid DNA and Lipofectamine 2000 (Invitrogen) were diluted in
Opti-MEM medium (Invitrogen) separately and were left in RT for 5 min before
they were mixed together. For T98G, U-2OS, and MIA PACA-2 cells, Dharma-
Fect Duo (Dharmacon) was used instead of Lipfectamine 2000 to minimize the
toxicity. The plasmid DNA and lipid mixture were incubated at RT for another
20 min to 1 hr. In the meantime, cells were trypsinized and resuspended in
complete cell growth medium without antibiotics before added to the incu-
bated DNA/lipid mixture. For siRNA transfection, siRNA was used instead of
plasmid DNA.
Luciferase Reporter Assay
T98G cells or HEK293T were transfected with a firefly luciferase reporter con-
struct, containing three NF-kB binding sites (a generous gift from Dr. Bing-
sheng Chang, UT Southwestern Medical Center at Dallas), together with
phRG-TK renilla luciferase reporter construct (Promega). Forty-eight hours
later, cells were treated as indicated in the figures. Cells were harvested after
additional 24 hr using Duo-Glo Luciferase Assay System (Promega) following
manufactory instruction.
Immunoprecipitation
For caspase-8 and FADD immunoprecipitation, caspase-8 antibody (Santa
Cruz Biotech, SC-1636) or FADD antibody (Santa Cruz Biotech, SC-5559)
was coupled to protein A agarose (Pierce) in PBS in the presence of 5 mg/
ml bovine serum albumin (Sigma) for 2 hr at room temperature. The pre-cou-
pled beads were then incubated with cell lysates over-night at 4C. The next
day, beads were washed with lysis buffer containing additional 300 mM
NaCl. The immunoprecipitants were eluted off the beads using low pH elution
buffer (Pierce) or 1 mg/ml caspase-8 peptide (FFIQACQGDNYQKGIPVETD)
(synthesized at Protein Chemistry Technology Center at UT Southwestern
Medical Center at Dallas, dissolved in buffer A) at room temperature for 1 hr.
Acid elution was neutralized by adding 1/20 volume of 1 M Tris-HCl, pH 9.4.
For Flag or HA pull-down, cell lysates were incubated with M2 Flag agarose
beads (Sigma), or HA agarose beads (Sigma), respectively, over-night at 4C.702 Cell 133, 693–703, May 16, 2008 ª2008 Elsevier Inc.The following day, beads were washed with lysis buffer containing additional
300 mM NaCl. The immunoprecipitants were eluted by directly boiling the
beads in SDS sample buffer.
Superose 6 Gel Filtration Analysis
Fifty microliter of caspase-8 peptide elution was directly loaded onto Smart
System superpose 6 gel filtration column (Amersham) equilibrated with buffer
A containing 500 mM NaCl and eluted with the same buffer. One hundred
microliter fractions were collected. Fifty microliter per fraction was used for
western blot analysis.
GST-TNF-a Pull-Down
Panc-1 cells were treated as indicated. Cells were harvested in lysis buffer
containing 1% CHAPS (Sigma) and incubated with Glutathione Sepharose
4B overnight at 4C. The following day, beads were washed with lysis buffer
containing 1% CHAPS and eluted by directly boiling in SDS sample buffer.
Biotinylated Smac Mimetic Pull-Down
Cell lysates were incubated with avidin agarose beads (Sigma) in the presence
of 100 nM biotinylated Smac mimetic overnight at 4C. The following day,
beads were washed with lysis buffer containing additional 300 mM NaCl.
The precipitants were eluted by directly boiling the beads in SDS sample
buffer.
SUPPLEMENTAL DATA
Supplemental Data include fifteen figures, Supplemental Experimental Proce-
dures, and Supplemental References and can be found with this article online
at http://www.cell.com/cgi/content/full/133/4/693/DC1/.
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